Blood samples from MS patients will be collected and assessed for the presence of MAP against control samples. Credit: National Cancer Institute / Unsplash.

MYND Life Sciences’ subsidiary MYND Diagnostics has begun a clinical study on the use of its proprietary biomarker test in Multiple Sclerosis (MS) diagnostics.

In this study, the anti-inflammatory peptide (MAP) biomarker test will be validated for diagnosing and monitoring MS.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Blood samples from MS patients will be collected and assessed for the MAP presence against control samples.

The clinical research is scheduled to begin in the first quarter of next year.

MYND Life Sciences CEO Dr Lyle Oberg said: “According to the National Multiple Sclerosis Society, at this time no symptoms, physical findings or laboratory tests can, by themselves, determine if you have MS.

“This makes MS such a challenging disease to diagnose; the wide variance of symptoms can make early detection difficult.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It is our goal through MYND Diagnostics’ clinical validation study targeting MS to provide health care practitioners with an objective diagnostic aid to help discover MS earlier and monitor treatment progress or regression.”

The company expects to submit an application to the US Food and Drug Association (FDA) for approval of the MAP biomarker test in the second half of next year, which would allow it to be made available to the public through healthcare providers.

MYND Life Sciences intends to help health care providers by offering a tool that can monitor and improve patient outcomes through personalised treatments.

Last month, MYND Life Sciences announced the formation of MYND Diagnostics to commercialise biomarker diagnostic tests for patients suffering from major depressive disorder, treatment-resistant depression and other inflammatory disorders of the central nervous system.